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Abstract
Introduction One of the main causes of death in European and
US intensive care units is sepsis. It involves a network of pro-
inflammatory cytokines such as TNF-α, IL-1β and IL-6.
Furthermore, there is an up regulation of transcription factors
such as nuclear factor (NF) κB. It has previously been shown
that clonidine is able to significantly reduce pro-inflammatory
cytokines in surgical patients. We therefore hypothesise that the
clinically used central alpha-2 agonist clonidine has the ability to
improve survival in experimental sepsis by inhibiting the
sympathetic tone and consequently inhibiting the pro-
inflammatory cytokine release.
Methods To investigate this therapeutic potential of clonidine in
a prospective randomised laboratory investigation we used a
murine model of caecal ligation and puncture (CLP) induced
sepsis. Animals receiving pre-emptive injections were treated
with either clonidine (5 μg/kg) or dexmedetomidine (40 μg/kg)
12 and 1 hours before the operation, as well as 1, 6 and 12
hours afterwards. Another group of animals only received
clonidine (5 μg/kg) 1, 6 and 12 hours after the operation, while
the pre-emptive injections were normal saline. The control
groups received solvent injections at the respective time points.
Results Pre-emptive administration of a central sympatholytic
significantly reduced mortality (clonidine: p = 0.015;
dexmedetomidine: p = 0.029), although postoperative
administration of clonidine failed to significantly prolong survival.
Furthermore pre-emptive administration of clonidine significantly
attenuated the cytokine response after CLP-induced sepsis
(mIL-1beta: p = 0.017; mIL-6: p < 0.0001; mTNF-α: p <
0.0001), preserved blood pressure control (p = 0.024) and
down-regulated the binding activity of NF-κB. There were no
changes in the pro-inflammatory cytokine response when
peripheral blood was incubated with lipopolysaccharide alone
compared with incubation with clonidine (10-4 M) plus LPS (p >
0.05).
Conclusions Our results demonstrate that the pre-emptive
administration of either clonidine or dexmedetomidine have the
ability to successfully improve survival in experimental sepsis.
Furthermore, there seems to be a connection between the
central muscarinic network and the vagal cholinergic response.
By down-regulating pro-inflammatory mediators sympatholytics
may be a useful adjunct sedative in patients with a high risk for
developing sepsis.
Introduction
The use of the central acting alpha-2 agonist clonidine has
become more popular since its introduction in the 1980s.
Besides its classical use to treat hypertension [1], its area of
use has spread further and is now used as an adjunct for epi-
dural analgesia [2] and to treat withdrawal [3] or migraines [4].
It is also given as a pre-medication before cardiac surgery to
treat cardiovascular fluctuations in high-risk patients [5]. Stud-
ies have shown that central acting alpha-2 agonists inhibit
noradrenergic neurotransmission and have a strong sedative
component secondary to sympathetic inhibition [6]. This for-
merly adverse side effect is nowadays widely used in critical
care settings to sedate patients and to reduce the amount of
co-medication needed. A recent study has shown the benefi-
Ach: acetylcholine; CLP: caecal ligation and puncture; ELISA: enzyme immunosorbent assay; EMSA: electrophoretic mobility shift assay; ICU: inten-
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cial effects of dexmedetomidine over lorazepam as an adjunct
sedative in a critical care setting [7]. Furthermore clonidine is
an integral part of the sedation regimen in German intensive
care units (ICU) [8].
The mechanism of action of central acting alpha-2 agonists
like clonidine is based on their ability to reduce the central
sympathetic tone by stimulating central alpha-2 receptors in
the medulla oblongata [7,9,10]. Therefore, the balance shifts
to the benefit of the parasympathetic nervous system. The
exact pathway is not yet known, but recent evidence points
towards the involvement of cerebral binding receptors for imi-
dazol in the signal transduction cascade of clonidine [9]. The
same mechanism of action is also true for dexmedetomidine,
which is even more specific in acting as a central alpha-2 ago-
nist [11].
Sepsis is one of the main causes of death in European and US
ICUs. The onset and perpetuation of inflammation involves a
complex network of cytokines such as TNF-α, IL-1β and IL-6,
causing upregulation of controlling transcription factors such
as nuclear factor-κB (NF-κB) [12,13]. Unbalanced overpro-
duction of these mediators provokes overwhelming reactions
resulting in systemic inflammation and eventually lethal multi-
organ failure [14].
Evidence that the clinically used medication clonidine has the
potential to be a prophylactic option in treating sepsis has
come from Kim and colleagues [15]. They have shown that
clonidine pre-medication is able to significantly reduce the
pro-inflammatory cytokines IL-1β and IL-6 in patients undergo-
ing hysterectomy. Another recent study has shown that cloni-
dine used as an adjunct sedative in critically ill patients was
able to reduce the occurrence of pneumonia in those patients
[16].
We therefore hypothesise that the clinically used central
alpha-2 agonist clonidine has the ability to improve survival in
experimental sepsis by inhibiting the sympathetic tone and
consequently inhibiting the release of the pro-inflammatory
cytokine.
Materials and methods
Caecal ligation and puncture
Caecal ligation and puncture (CLP) was performed as
described previously [17-20] after approval by the appropriate
local review committee and in compliance with governmental
guidelines. In brief, female C57BL/6 mice aged 12 to 16
weeks were anaesthetised by intraperitoneal administration of
100 mg/kg ketamine (Ketanest, Pfizer Pharma, Karlsruhe, Ger-
many). The caecum was exposed through a 1.0 to 1.5 cm
abdominal midline incision and subjected to a ligation 6 mm
from the caecal tip followed by a single puncture with a G23
needle. A small amount of stool was expelled from the punc-
ture to ensure patency. The caecum was returned into the peri-
toneal cavity and the abdominal incision was closed by layers
with 5/0 prolene thread (Ethicon, Norderstedt, Germany). No
antibiotics were administered in this model. For the sham-
operated mice serving as controls, the caecum was mobilised
but no ligation or puncture was performed.
Animals receiving pre-emptive injections were treated with
either clonidine (5 μg/kg) or dexmedetomidine (40 μg/kg) 12
and 1 hours before the operation, as well as 1, 6 and 12 hours
afterwards. Another group of animals only received clonidine
(5 μg/kg) 1, 6 and 12 hours after the operation, while the pre-
emptive injections were of normal saline. The control groups
for each intervention received solvent (0.9% saline) injections
at the corresponding time points. All injections were given
intra-peritoneal. CLP was performed blinded to the identity of
the treatment group. Survival after CLP was assessed four to
six times a day for at least five days. Blood pressure was meas-
ured in anaesthetised mice with femoral manometric catheters
0, 6 and 24 hours after CLP.
To harvest blood for determination of cytokines, mice from the
pre-emptive clonidine group and their corresponding controls
were deeply anaesthetised by intraperitoneal injections of 30
μl/g Avertin (stock: 1 g tribromethanol/620 μl 2-methyl-1-buta-
nol, 180 μl per 10 ml 0.9% sodium chloride (Braun, Melsun-
gen, Germany)) 24 hours after CLP. To conduct
electrophoretic mobility shift assay (EMSA) analysis and
ELISA, the liver was immediately snap-frozen in liquid nitrogen.
Electrophoretic mobility shift assay
Nuclear proteins from snap-frozen mouse tissues were iso-
lated as described in detail elsewhere [21]. Nuclear extracts
were assayed for NF-kB binding activity using the consensus
sequence 5'-AGT TGA GGG GAC TTT CCC AGG C-3'
labelled by [g-32P]-dATP and T4-kinase to a specific activity
more than 5 × 10 cpm/μg. Specificity of binding was ascer-
tained by competition with a 160-fold molar excess of unla-
belled consensus oligonucleotides. Protein-DNA complexes
were separated from unbound DNA probes by electrophoresis
through 5% native polyacrylamide gels containing 2.5% glyc-
erol and 0.5× tris-borate EDTA. Gels were dried and exposed
to x-ray films (Amersham Pharmacia, Freiburg, Germany) at 
-80°C using intensifying screens for 48 to 60 hours.
In vitro incubation of whole blood samples
The ethical principles as set out in the Declaration of Helsinki
were honoured in the present study, which was approved by
the ethics committee of the University of Heidelberg (S-123/
2008). Venous blood was drawn from the antecubital vein of
healthy volunteers after giving their informed consent. After
discarding the first 2 mL, blood was collected in one 10th vol-
ume of citrate (3.8%, Becton Dickinson Vacutainer, New Jer-
sey, USA) and samples were immediately used for the
experiments. The samples were incubated for 24 hours either
with lipopolysaccharide (1 μg) alone, with clonidine alone (10-Available online http://ccforum.com/content/13/1/R11
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4 M) or with LPS (1 μg) plus clonidine (10-4 M). In the latter
experiments clonidine was added one hour before LPS admin-
istration. This was followed by centrifugation for 10 minutes at
2000 rpm, the serum was frozen at -80°C until ELISA was per-
formed
ELISA
Plasma and supernatants were subjected to ELISA for deter-
mination of Il-1β, Il-6 and TNF-α contents. ELISA kits were pur-
chased from R&D Systems GmbH (Wiesbaden-Nordenstadt,
Germany) and used according to the manufacturer's instruc-
tions.
Statistical analysis
Where indicated, values of experimental groups are given as
the mean, with bars showing the standard error of the mean
(SEM). The means of the groups were compared by analysis
of variance using the Student's t-test. When Kaplan-Meier
estimates of group survival distributions are shown, the
logrank test was used to compare two or more survival distri-
butions. A result was denoted as statistically significant if the
p-value of its corresponding test statistic was less than 0.05.
All statistical computations were performed using Prism
Graph (Version 5; GraphPad Software, La Jolla, CA., USA).
Results
Pre-emptive injection of the central acting alpha-2 
agonist clonidine or dexmedetomidine improves survival 
in experimental sepsis
The mice received a total of five injections of clonidine (5 μg/
kg) intraperitoneally. The injections were given 12 hours and 1
hour before CLP and 1 hour, 6 hours and 12 hours after the
intervention. The control group received solvent injections.
Clonidine-treated animals survived significantly longer than
control mice (p = 0.015; Figure 1). Notably, after survival of the
initial phase, there were no further drop-outs within an obser-
vation period of five days, indicating a true resolution of sepsis
rather than delaying kinetics.
We then tested if pre-emptive injection of the more specific
central acting alpha-2 agonist dexmedetomidine would be suf-
ficient to reduce mortality from sepsis. We therefore injected
40 μg/kg of dexmedetomidine 12 hours and 1 hour before and
1 hour, 6 hours and 12 hours after CLP and compared it with
Figure 1
Survival after caecal ligation and puncture (CLP)-induced sepsis Survival after caecal ligation and puncture (CLP)-induced sepsis. Kaplan-Meier survival curves of mice after CLP-induced sepsis (t = 0). (a) Pre-
emptive administration of clonidine improves survival after CLP-induced sepsis. The verum group (solid line, n = 30) received clonidine (5 μg/kg) 12 
hours and 1 hour before CLP, as well as 1 hour, 6 hours and 12 hours after CLP. The control group received corresponding injections with solvent 
(dashed line, n = 30). Clonidine-treated animals survived significantly longer than their controls (p = 0.015, n = 60). (b) Pre-emptive administration 
of dexmedetomidine statistically prolongs survival after CLP-induced sepsis. The verum group (solid line, n = 40) received dexmedetomidine (40 μg/
kg) 12 hours and 1 hour before CLP, as well as 1 hour, 6 hours and 12 hours after CLP. The control group received corresponding injections with 
solvent (dashed line, n = 40). Dexmedetomidine-treated animals survived significantly longer than their controls (p = 0.029, n = 80). (c) Post-opera-
tive administration of clonidine does not improve survival after CLP-induced sepsis. The verum group (solid line, n = 30) received clonidine (5 μg/kg) 
1 hour, 6 hours and 12 hours after CLP. The control group received corresponding injections with solvent (dashed line, n = 30). There was no sta-
tistically significant difference between both groups (p = 0.228, n = 60). * indicates statistical significant differences between the groups.Critical Care    Vol 13 No 1    Hofer et al.
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injection of solvent. Animals treated with dexmedetomidine
survived significantly longer than the ones treated with solvent
(p = 0.029; Figure 1).
We have shown above that pre-treatment with clonidine signif-
icantly improves survival in experimental sepsis if given pre-
emptively before CLP. To further test if administration of cloni-
dine after CLP would still be protective, we compared cloni-
dine injections (5 μg/kg), given 1 hour, 6 hours and 12 hours
after CLP, with solvent injections. The effect seen was much
less pronounced compared with clonidine given before CLP.
Mean survival times and Kaplan Meier survival curves showed
no statistical difference (p = 0.228).
Pre-emptive injection of clonidine reduces the 
generation of pro-inflammatory mediators, namely mIL-
1β, mIL-6 and mTNF-α
We further investigated if the improved survival in the group
pre-emptively treated with clonidine was correlated with
decreased pro-inflammatory mediators. We elicited that exper-
imental sepsis leads to a profound increase in mIL-1β in
mouse serum 24 hours after CLP. This increase could be
markedly attenuated by pre-emptive treatment with clonidine
injections as described above (p = 0.017; Figure 2). The same
effect could also be observed when mIL-6 was measured 24
hours after CLP. The increase initiated by sepsis was signifi-
cantly reduced by pre-emptive clonidine injections (p <
0.0001; Figure 2). Furthermore the rise of the pro-inflamma-
tory marker mTNF-α following CLP-induced sepsis was also
significantly reduced by clonidine (p < 0.0001; Figure 2).
Those findings suggest that the decrease of the proinflammaty
mediators mIL-6, mIL-1β and mTNF-α might contribute to the
reduced mortality seen after clonidine injections.
Pre-emptive injection of clonidine preserves blood 
pressure control in septic animals
To exclude that the effects of clonidine are attributed to the
induction of hypotension we additionally monitored blood
pressure in mice receiving pre-emptive administration of cloni-
dine and compared it with mice only receiving normal saline
(control group) at the corresponding time points (n = 12 for
each group). At baseline (performance of CLP), blood pres-
sures did not differ between both groups (114.0 ± 9.9 mmHg
Figure 2
Clonidine attenuates cytokine response after caecal ligation and puncture (CLP)-induced sepsis Clonidine attenuates cytokine response after caecal ligation and puncture (CLP)-induced sepsis. Mice in the verum group (n = 10) received cloni-
dine (5 μg/kg) 12 hours and 1 hour before CLP, as well as 1 hour, 6 hours and 12 hours after CLP. The control group (n = 10) received injections 
with solvent respectively. (a) Pre-emptive administration of clonidine decreases mIL-1β levels after CLP induced sepsis. Experimental sepsis led to a 
profound increase in mIL-1β in mouse serum 24 hours after CLP. This increase was significantly attenuated by pre-emptive clonidine injections (p = 
0.017) as described above. (b) Pre-emptive administration of clonidine decreases mIL-6 levels after CLP induced sepsis. Experimental sepsis led to 
a profound increase in mIL-6 in mouse serum 24 hours after CLP. This increase was significantly attenuated by pre-emptive clonidine injections (p < 
0.0001) as described above. (c) Pre-emptive administration of clonidine decreases mTNF-α levels after CLP-induced sepsis. Experimental sepsis 
led to a profound increase in TNF-α in mouse serum 24 hours after CLP. This increase was significantly attenuated by pre-emptive clonidine injec-
tions (p < 0.0001) as described above. * indicates statistical significant differences between the groups.Available online http://ccforum.com/content/13/1/R11
Page 5 of 8
(page number not for citation purposes)
versus 109.7 ± 3.2 mmHg; p = 0.69). Furthermore, there was
no difference between the two groups after six hours (97.0 ±
3.4 mmHg versus 96.1 ± 6.0 mmHg; p = 0.90) and there was
no difference when compared with baseline (control group,
baseline versus six hours: p = 0.08 and clonidine, baseline ver-
sus six hours: p = 0.10). However, after 24 hours mice receiv-
ing a pre-emptive administration of clonidine had relatively
preserved blood pressures when compared with baseline
(93.7 ± 4.6 mmHg versus 109.7 ± 3.2 mmHg; p = 0.02) while
the control animals were significantly hypotensive when com-
pared with baseline (114.0 ± 9.9 mmHg versus 76.4 ± 5.4
mmHg; p = 0.002) and also when compared with animals pre-
emptively treated with clonidine (76.4 ± 5.4 mmHg versus
93.7 ± 4.6 mmHg; p = 0.024).
These results show that clonidine is not causing significant
hypotension that contributes to its effect of prolonging survival
or lowering cytokine response. In fact the pre-emptively
treated animals have less hypotension caused by sepsis than
the untreated ones, which points towards the protective effect
of clonidine being independent of its ability to lower blood
pressure.
Pre-emptive injection of clonidine reduces NF-κB 
activation
In addition to increased pro-inflammatory mediators measured
in blood, CLP also leads to a strong increase in NF-κB binding
activity assayed with EMSA in the liver (Figure 3). In contrast,
in mice treated with clonidine we found no difference in NF-κB
binding activity compared with mice receiving placebo injec-
tions with saline (Data not shown). Furthermore, there was no
difference between mice with CLP-induced sepsis receiving
clonidine and sham-operated animals (n = 6 for each group;
Figure 3). This further contributes to the hypothesis that the
survival improving effect of clonidine might be related to a
decrease in pro-inflammatory mediators.
Clonidine has no effect on cytokine production in LPS 
stimulated whole blood
Next we tested if the effects described above were because
of clonidine's central acting mechanism of action or mediated
peripherally. Therefore, we incubated whole blood samples of
healthy donors (n = 4) for 24 hours with either LPS (1 μg)
alone, or clonidine (10-4) alone or LPS plus clonidine (10-4). As
pro-inflammatory markers we choose IL-1β, IL-6 and TNF-α, as
in the animal experiments. Administration of clonidine alone
had no effect on the concentrations of either mediator chosen,
compared with untreated controls (data not shown). Incuba-
tion with LPS on the other hand (100 μg/ml) showed a marked
increase of each mediator compared with the untreated con-
trols (LPS alone versus untreated control: p = 0.0005; Figure
4). This increase of IL-1β after LPS incubation did not signifi-
cantly differ from incubation with LPS plus clonidine (LPS
alone versus LPS plus clonidine 10-4: p = 0.89; Figure 4). The
same was true for IL-6, which increased about the same
amount after incubation with LPS alone or with LPS plus clo-
nidine (LPS alone versus untreated control: p = 0.0001; LPS
alone versus LPS plus clonidine 10-4: p = 0.88; Figure 4).
Measurements of TNF-α also increased after the administra-
tion of LPS alone but this was not statistically different from
administration of LPS and clonidine combined (LPS alone ver-
sus untreated control: p = 0.025; LPS alone versus LPS plus
clonidine 10-4: p = 0.99; Figure 4).
The previously found data combined with the data above sup-
ports that the improved survival of CLP-induced sepsis in clo-
nidine-treated animals is mediated centrally. This points to the
importance of the balance between the sympathetic and par-
asympathetic nervous system in mediating an inflammatory
response.
Discussion
We have shown in this study that pre-emptive administration
of clonidine or dexmedetomidine is able to significantly
improve survival in sepsis induced by CLP. This is accompa-
nied by a reduction in the pro-inflammatory mediators IL-1β, IL-
6 and TNF-α, as well as a decrease in NF-kB binding activity,
thereby inhibiting an overwhelming inflammation response to
sepsis.
The use of central alpha-2 agonists as an adjunct sedative in
critically ill patients in an ICU setting has been discussed in the
scientific literature [7,8,11]. A first hint that sympatholytics are
beneficial in sedating ICU patients comes from Pandhari-
pande and colleagues who additionally refer to a vagomimetic
component of dexmedetomidine [7]. They have shown that
Figure 3
Clonidine reduces nuclear factor (NF) κB activation after caecal ligation  and puncture (CLP)-induced sepsis Clonidine reduces nuclear factor (NF) κB activation after caecal ligation 
and puncture (CLP)-induced sepsis. The figure shows NF-κB binding 
activity, as assessed by electrophoretic mobility shift assay (EMSA) 
assay in the livers of mice that underwent CLP surgery. CLP led to a 
strong increase in NF-κB binding activity. In contrast, in mice treated 
with clonidine we found no difference in NF-κB binding activity com-
pared with mice receiving placebo injections with normal saline. Fur-
thermore, there was no difference between mice with CLP-induced 
sepsis receiving clonidine and sham-operated mice. Group I 'Sham 
OP'; EMSA for NF-κB binding activity; liver tissue. Group II 'CLP + clo-
nidine', clonidine therapy, EMSA for NF-κB binding activity; liver tissue. 
Group III: 'CLP + placebo', saline injection, EMSA for NF-κB binding 
activity; liver tissueCritical Care    Vol 13 No 1    Hofer et al.
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sedation with dexmedetomidine instead of lorazpam not only
leads to significantly less delirum or coma, but also improves
survival in those patients. Unfortunately, they did not report the
incidence of sepsis in their patients. Another recent study,
however, was able to show that patients treated with clonidine
for alcohol withdrawl had significantly less pneumonia than
those treated without a sympatholytic agent [16].
To determine the exact survival benefit in sepsis after sympa-
thetic inhibition, we performed CLP, which causes lethal peri-
tonitis by microbial infection and is a valid animal model for
human sepsis [20,22]. Pre-emptive administration of either
clonidine or dexmedetomidine was potent enough to signifi-
cantly reduce mortality in CLP-induced sepsis. This supports
the reasoning to consider the use of a sympatholytic drug as
an adjunct sedative in both high-risk patients before undergo-
ing major surgery and in ICU patients prone to sepsis. When
the administration of clonidine was delayed until after the oper-
ation, no further protective effect could be elicited. This is con-
sistent with previous studies that also failed to show a
protective effect of late activation of the cholinergic anti-inflam-
matory pathway [23]. It contradicts the findings of Wang and
colleagues [22] who demonstrated that nicotine treatment
could be delayed for 24 hours after sepsis induction. This
might be at least in part explained by the use of antibiotics in
the study, whereas our animals did not receive any antibiotic
treatment. Also different mice strains were used in that study
which may be different in the susceptibility to CLP-induced
peritonitis.
The improved survival in pre-emptively treated animals corre-
lates with a reduction in NF-κB binding activity shown by
EMSA. This corresponds to previous findings, showing a sim-
ilar blunting of the NF-κB pathway on activation of the cholin-
ergic anti-inflammatory pathway [22]. It is well known that most
inflammatory signals merge in activation of the NF-κB pathway
and NF-κB has been shown to play a critical role in modulating
mortality in experimental [20] and clinical sepsis [24]. Thus,
the elicited down-regulation of NF-κB binding activity after clo-
nidine administration is a potential explanation for the
improved survival in CLP-induced sepsis as shown here.
Furthermore pre-emptive administration of clonidine signifi-
cantly reduced the pro-inflammatory mediators TNF-α, IL-6
and IL-1β, although these pro-inflammatory cytokines were still
detectable in considerable concentrations. However, it has
been shown that complete elimination of TNF-α after CLP-
induced sepsis coincides with increased mortality [17,19].
Although increased levels of IL-6 seem to be predictive for
poor survival and increased infectious complications [25].
Sympatholysis might therefore be sufficient to reduce cytokine
levels low enough to prevent septic shock and consecutive
Figure 4
Whole blood incubation with lipopolysaccharide and clonidine respectively Whole blood incubation with lipopolysaccharide and clonidine respectively. Whole blood samples of healthy donors (n = 4) were incubated for 24 
hours with either LPS alone (1 μg) or LPS (1 μg) plus clonidine (10-4). (a) IL-1β levels after whole blood incubation with LPS and clonidine respec-
tively. The concentration of IL-1β increased significantly after LPS administration compared with untreated controls (p = 0.0005). There was no sta-
tistically significant difference in IL-1β levels between samples treated with LPS alone and those incubated with LPS plus clonidine (10-4; p = 0.89). 
(b) IL-6 levels after whole blood incubation with LPS and clonidine respectively. The concentration of IL-6 increased significantly after LPS adminis-
tration compared with untreated controls (p = 0.0001). There was no statistically significant difference in IL-6 levels between samples treated with 
LPS alone and those incubated with LPS plus clonidine (10-4; p = 0.88). (c) TNF-α levels after whole blood incubation with LPS and clonidine 
respectively. The concentration of TNF-α increased significantly after LPS administration compared with untreated controls (p = 0.025). There was 
no statistically significant difference in TNF-α levels between samples treated with LPS alone and those incubated with LPS plus clonidine (10-4; p 
= 0.99). * indicates statistical significant differences when compared with untreated.Available online http://ccforum.com/content/13/1/R11
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death. It might also be necessary not to decrease cytokines
too low in order to be sufficient for clearing bacterial infec-
tions.
Our study showed that peripheral in vitro administration of clo-
nidine is not sufficient to reduce the pro-inflammatory
cytokines measured. This finding supports the hypothesis that
the beneficial effect of clonidine is not peripherally mediated
but rather based on its ability to centrally activate alpha-2
receptors and thereby decrease sympathetic tone [6]. To date,
the role of the balance between the sympathetic and parasym-
pathetic nervous system has not been readily established.
Recent studies, however, have suggested that there seems to
be a connection between the central muscarinic network and
the vagal cholinergic response [26], influencing each other.
Furthermore, it has been shown that activation of the choliner-
gic anti-inflammatory pathway by vagal stimulation can be uti-
lised to protect against experimental sepsis [22,23,27,28].
This was performed either directly by injection of nicotine [20],
electrical stimulation of the vagal nerve [27] or indirectly by
increasing the amount of acetylcholine (Ach) [23]. Our study
points toward the possibility that direct sympatholysis might
be sufficient enough to activate this pathway. It is interesting
that the effect of clonidine does not correlate with significant
hypotension that contributes to prolonging survival and lower-
ing cytokine response. In fact the pre-emptively treated ani-
mals have improved blood pressure control and less
hypotension than untreated ones.
Our study is limited by the use of ketamine as an anaesthetic
for the CLP procedure. Ketamine is a noncompetitve inhibitor
of the nicotinic Ach-receptor [29] that might leave the receptor
unresponsive to Ach elevations induced by changes in vagal
tone. However, in our study, animals received only a single
dose of ketamine and the elimination half time of ketamine is
about three hours. This might have attenuated the effects
observed for the treatment with clonidine, which might have
been even more pronounced if anaesthesia had been
achieved using a different drug. Furthermore, there is also sig-
nificant modulation of the Ach-haemostasis during surgical
interventions.
Nevertheless, pre-emptive administration of either clonidine or
dexmedetomidine was potent enough to significantly reduce
mortality in CLP-induced sepsis. This supports the rationale to
use clonidine or dexmedetomidine as an adjunct sedative in an
ICU setting in order to reduce the occurrence of sepsis. Fur-
thermore, administration of a central acting alpha-2 agonist
might be considered as a pre-emptive therapeutic option in
high-risk patients undergoing major surgery.
Conclusions
We demonstrate that the clinically used central acting alpha-2
agonists clonidine and dexmedetomidine improve survival in
murine experimental sepsis. This is most probably due to their
sympatholytic effects that lead to down-regulation of pro-
inflammatory mediators. Our findings provide a rationale for
further exploration and may have important implications for the
use of clonidine or dexmedetomidine as adjunct sedatives in
the pre-emptive treatment of patients with a high risk for devel-
oping sepsis.
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